Compared with patients with BRAFWT tumours, those with BRAFMUT tumours have significantly higher likelihood of disease progression (P<0.0001) or death (P<0.0001) with any current regimen (Table 3); the BRAF V600E mutation predicted independently for early relapse on first-line therapy (HR 4.0, 95% CI 2.2–7.4) and death (HR 4.0, 95% CI 2.1–8.0). Here, BRAF is linked to neoplasm.